GSDMD and metabolic dysfunction-associated steatohepatitis: In addition, the decreased expression of ASC, caspase-1 p20, and GSDMD suppressed the hepatocyte pyroptosis pathway, which improved the inflammation, steatosis, and cell damage associated with pyroptosis, thereby alleviating NASH.